If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTransense Regulatory News (TRT)

Share Price Information for Transense (TRT)

Share Price is delayed by 15 minutes
Get Live Data
48.50    0.00 (0.00%)
Bid:
48.00
Ask:
49.00
Spread: 1.00 (2.083%)
Market Cap: £7.38m
TRT Live PriceLast checked at - London Stock Exchange

Intraday Transense Share Chart

Board Changes

Today 07:00

RNS Number : 2289L
Transense Technologies PLC
07 July 2026
 

7 July 2026

Transense Technologies plc

("Transense" or the "Company")

Board Changes

Retirement of Chief Financial Officer and Appointment of Finance Director (designate)

Transense Technologies plc (AIM: TRT), the provider of specialist sensor technology and measurement solutions, announces that Melvyn Segal has informed the Board of his intention to retire from the role of Chief Financial Officer ("CFO") and Company Secretary with effect from the Company's Annual General Meeting (AGM) in November 2026. The Board also announces the appointment of Richard Michael Pearce ACA as Finance Director with effect from 1 September 2026.

Melvyn will remain with the Company in an executive capacity for a handover period until the AGM, and will subsequently remain on the Board as a non-executive director for a further year. The Board would like to thank Melvyn for his significant contribution to Transense over many years, during which the Company and its prospects have been transformed.

Richard brings over twenty years of financial, commercial and listed company experience to Transense. Since qualifying as a Chartered Accountant with Ernst & Young in 1999, he has held senior finance roles at GE Healthcare and TD Williamson, and most recently as Finance Director at Lombard Medical where he oversaw a scale-up in revenues from £6m to £25m per annum since 2018. He will initially work alongside Melvyn in a non-board role as Finance Director, with progression to the Board leading the Group's finance function when Melvyn's steps down as CFO in November 2026.

The Board welcomes Richard to his new role and we look forward to his contribution to delivery of the future growth strategy.

For further information please visit www.transense.com or contact:

Transense Technologies plc

Nigel Rogers (Executive Chairman)

Ryan Maughan (Managing Director)

Melvyn Segal (Chief Financial Officer)

Via Investor Relations

(see below)

Cavendish Capital Market Limited (Nominated Adviser and Broker)

Adrian Hadden / Callum Davidson (Corporate Finance)

Jasper Berry (Sales)

0207 220 0500

Investor Relations

Anice McNamee

Tel: +44 (0)1869 238380

Investor.relations@transense.co.uk

Notes to Editors:

Transense is headquartered in Oxfordshire, UK and its shares are traded on AIM, a market operated by the London Stock Exchange (AIM: TRT). The Company develops and supplies advanced sensor technology and measurement solutions used by some of the world's leading companies to improve performance, efficiency, and safety in demanding, mission critical applications. Transense currently operates through two active business segments:

· SAWsense - designs, supplies and licences advanced sensor solutions based on proven, patent protected Surface Acoustic Wave (SAW) technology to world leading companies in aerospace, automotive, and industrial machinery (including robotics), enabling improved efficiency and performance of their products. Key customers include GE Aerospace, Parker Meggitt, McLaren Applied, Airbus and several other confidential Tier One automotive, aerospace and industrial machinery suppliers.

 

· Translogik - develops smart, connected commercial vehicle tyre inspection equipment to many of the world's leading tyre suppliers, fleet operators and service centres. Enabling accurate measurement and digital capture of safety-critical tyre condition data, used to reduce operating costs, improve safety and provide audit records for regulatory compliance. Key customers include Bridgestone, Goodyear, Continental and Prometeon (Pirelli), and leading independent providers of vehicle fleet maintenance management software.

 In addition, Transense earns residual royalty income from Bridgestone iTrack - a tyre monitoring system for off-highway vehicles that was developed by Translogik. The associated sales, support and development infrastructure were sold to Bridgestone Corporation, the world's largest tyre producer, in June 2020, and the intellectual property was licensed exclusively to Bridgestone under a ten-year deal expiring in 2030.

Find out more at: https://www.transense.com/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAAKABQCBKDDOK
Date   Source Headline
16th Oct 20233:23 pmRNSHolding(s) in Company
3rd Oct 20236:00 pmRNSHolding(s) in Company
28th Sep 20235:22 pmRNSHolding(s) in Company
27th Sep 20233:18 pmRNSHolding(s) in Company
26th Sep 20233:37 pmRNSDirector/PDMR Shareholding
25th Sep 202311:00 amRNSDirector/PDMR Shareholding
25th Sep 20237:00 amRNSFinal Results & Investor Presentation
22nd Sep 20239:25 amRNSHolding(s) in Company
31st Aug 20235:00 pmRNSTotal Voting Rights
29th Aug 20238:30 amRNSTransaction in Own Shares & TVR
23rd Aug 20237:00 amRNSNotice of Results & Investor Presentation
16th Aug 202310:03 amRNSHolding(s) in Company
11th Jul 20237:00 amRNSYear End Trading Update
30th Jun 20235:00 pmRNSTotal Voting Rights
22nd Jun 20234:24 pmRNSTransaction in own shares & TVR
19th Jun 20234:29 pmRNSHolding(s) in Company
16th Jun 20235:57 pmRNSTransaction in own shares & TVR
5th Jun 20237:00 amRNSSAW: Extension of scope of licence agreement
2nd Jun 20232:36 pmRNSTransaction in own shares & TVR
31st May 20235:00 pmRNSTotal Voting Rights
3rd May 20237:00 amRNSNew Automotive eDrive Business Contract
2nd May 202312:48 pmRNSAppointment of Non-Executive Director
2nd May 202310:23 amRNSTransaction in own shares & TVR
31st Mar 20235:00 pmRNSTotal Voting Rights
27th Mar 20237:00 amRNSGrant of share options to Director and employees
20th Mar 20238:49 amRNSTransaction in Own Shares & TVR
20th Mar 20237:00 amRNSTransaction in Own Shares & TVR
13th Mar 20232:49 pmRNSTransaction in Own Shares & TVR
13th Mar 20237:00 amRNSDirectorate and Management Changes
22nd Feb 202310:52 amRNSDirector/PDMR Shareholding - acquisition of shares
22nd Feb 20237:00 amRNSInterim Results & Investor Presentation
7th Feb 20237:00 amRNSNotice of Results & Investor Presentation
30th Dec 20227:00 amRNSTotal Voting Rights
19th Dec 20226:22 pmRNSDirector/PDMR Shareholding
7th Dec 20222:10 pmRNSHolding(s) in Company
5th Dec 20227:00 amRNSTransaction in Own Shares & TVR
1st Dec 202212:03 pmRNSResult of AGM
1st Dec 20227:00 amRNSAGM Trading Update
30th Nov 20225:00 pmRNSTotal Voting Rights
14th Nov 20222:51 pmRNSTransaction in Own Shares & TVR
31st Oct 20225:00 pmRNSTotal Voting Rights
24th Oct 20227:00 amRNSPosting of Annual Report & Notice of AGM
17th Oct 20227:00 amRNSTransaction in Own Shares & TVR
4th Oct 20221:44 pmRNSHolding(s) in Company
27th Sep 202211:05 amRNSSecond Price Monitoring Extn
27th Sep 202211:00 amRNSPrice Monitoring Extension
27th Sep 20227:01 amRNSShare Repurchase Programme
27th Sep 20227:00 amRNSFinal Results & Investor Presentation
13th Sep 20227:00 amRNSMoU with Meggitt SA for SAW in aerospace sector
12th Sep 20227:00 amRNSNotice of Results, Investor Pres, AGM & Site visit

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.